Today: 19 November 2025
Subscribe
Browse Tag

Obesity

Pfizer Stock News Today (PFE): Texas ADHD Settlement, New Antibody Partnership and Obesity Push – November 19, 2025

Pfizer Stock News Today (PFE): Texas ADHD Settlement, New Antibody Partnership and Obesity Push – November 19, 2025

Pfizer (NYSE: PFE) headlines today include a $41.5 million ADHD drug settlement with Texas, a new antibody discovery deal with Nona Biosciences, and fresh guidance on cost cuts and obesity drugs from the Jefferies Healthcare Conference — here’s what it all means for PFE stock on November 19, 2025. Key Takeaways for Pfizer Investors Today Pfizer Stock Today: How PFE Is Trading on November 19, 2025 Ahead of and shortly after the open on Wednesday, November 19, 2025, Pfizer shares (NYSE: PFE) are hovering around the $25–26 range. MarketWatch shows pre‑market trading near $25.37, modestly below the prior close at
19 November 2025
 ·  ·  ·  ·  · 
Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

Viking Therapeutics (VKTX) on Nov. 11, 2025: Stifel Fireside Chat Today, Fresh VK2735 Obesity Data From ObesityWeek, and Phase 3 VANQUISH Progress

Published: November 11, 2025 Viking Therapeutics, Inc. (NASDAQ: VKTX) steps into the spotlight today with a scheduled fireside chat at the Stifel 2025 Healthcare Conference in New York (4:40–5:10 p.m. ET). The appearance comes on the heels of new clinical analyses from ObesityWeek® 2025 and an October corporate update outlining steady Phase 3 progress for its lead obesity candidate, VK2735. Viking Therapeutics InvestorRoom What’s happening today (Nov. 11) Viking’s management will host a fireside chat and hold 1×1 investor meetings at Stifel’s conference, part of a busy November investor-relations calendar that also includes a corporate presentation at the Jefferies 2025
11 November 2025
 ·  ·  ·  ·  · 
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Background: Novo vs. Pfizer in the Weight-Loss Drug Race The fight for Metsera is driven by fierce competition in GLP-1 obesity drugs. Novo Nordisk is the maker of Wegovy/Ozempic, and Eli Lilly’s drugs recently overtook Wegovy in US market share reuters.com. Novo’s new CEO Mike Doustdar and the company’s controlling foundation have pushed for bolder moves after days of sliding market performance reuters.com reuters.com. In late October, Novo – which had already agreed a separate $5 billion deal to buy diabetes biotech Akero – suddenly “launched a bid…valuing [Metsera] at some $9 billion and crashing Pfizer’s deal” reuters.com. This was weeks
4 November 2025
 ·  ·  ·  ·  ·  · 
Pfizer Stock Surges on Trump’s Drug Price Deal & $7B Obesity Gamble – Is This the Comeback Investors Hoped For?

Pfizer Stock Surges on Trump’s Drug Price Deal & $7B Obesity Gamble – Is This the Comeback Investors Hoped For?

Technical Analysis – Levels to Watch From a technical perspective, Pfizer’s stock has been basing in the low-to-mid $20s and has yet to break out of its longer-term downtrend. The 52-week range is roughly $20.92 to $30.43 ts2.tech, and the late-September rally stalled out near the upper-$20s – a zone that now acts as an overhead resistance (around $26–$27). Notably, PFE is trading below its 200-day moving average (~$27), indicating lingering bearish momentum trefis.com. On the upside, a decisive push above the $27–$28 level (and the 200-day MA) would be a bullish signal that the stock’s trend is turning. In
1 November 2025
 ·  ·  ·  ·  · 
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Rockets 51% on Obesity Pill Breakthrough and $1B Pharma Deal

Stock Price and Recent Performance RANI has seen explosive moves this month. As of the Oct 31 close, Rani Therapeutics stock was $2.20 (up $0.75, +51.7%) stockanalysis.com. This follows a monumental rally: on Oct 17, RANI nearly tripled from ~$0.47 to an intraday high of $2.39 (+248%) ts2.tech stockanalysis.com after the company announced the Chugai collaboration and financing. Even after that spike, RANI remained volatile – it spent mid-October around $1.50–2.50, briefly crossing Nasdaq’s $1 bid threshold and greatly lifting its market cap. Volume has been extremely high: for example, ~172 million shares traded on Oct 20 and ~124 million on Oct 21 stockanalysis.com, versus
31 October 2025
 ·  ·  ·  ·  · 
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk hijacks Pfizer’s Metsera deal with a $9B bid – obesity-drug war heats up

Novo’s counter-offer details Novo Nordisk’s proposal is unsolicited, meaning Metsera’s board and shareholders will now review it against Pfizer’s agreement. Novo emphasizes that Metsera’s experimental therapies would be “complementary” to its own obesity portfolio reuters.com. According to MarketScreener (Dow Jones Newswires), the bid is $56.50 in cash per Metsera share plus $21.25 in milestone CVRs marketscreener.com. By contrast, Pfizer’s September deal was $4.9B upfront (about $28.50/share) plus CVRs, for up to ~$7.3B ts2.tech reuters.com. Novo’s offer thus values the company at roughly $6.5B upfront, sweetened to ~$9B with earnouts. Novo’s CEO Maziar “Mike” Doustdar hailed the move as proof of
30 October 2025
 ·  ·  ·  ·  ·  · 
Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Sources: CPHI Frankfurt event coverage contractpharma.com gxpnews.net; GxP News gxpnews.net gxpnews.net; The Medicine Maker/Conexiant conexiant.com conexiant.com; GlobeNewswire (Hengdian/Apeloa) globenewswire.com; Evaluate Pharma forecast evaluate.com evaluate.com; Reuters reuters.com; TechStock² / TS2 Tech ts2.tech ts2.tech; TS2 Tech ts2.tech ts2.tech.
28 October 2025
 ·  ·  ·  · 
Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Pfizer (PFE) Stock Rebounds on Trump Drug Deal & Obesity Gamble – Can the Rally Last?

PFE Stock Price and Recent Performance Pfizer’s stock has endured a rough 2025, trading in the low-to-mid $20s for much of the year and touching multi-year lows. By late September, PFE was around $23.60 – down ~9% year-to-date and ~18% from a year prior ts2.tech. It languished near the bottom of its 52-week range ($20.92 – $30.43) ts2.tech as the company faced a post-pandemic hangover: revenues from its COVID-19 vaccine (Comirnaty) and pill (Paxlovid) plummeted from $37.8B in 2022 to about $12.5B in 2024 ts2.tech. Wall Street projected Pfizer’s EPS would fall by more than half from 2022 to 2025
27 October 2025
 ·  ·  ·  ·  · 
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer Stock Soars After Trump’s Drug Deal and Obesity Bet – Is This the Start of a Comeback?

Stock Performance: From Laggard to Late-September Lift For much of 2025, Pfizer’s stock was stuck in a rut – but that changed dramatically as Q4 approached. By late September, PFE had drifted down near multi-year lows around $23, reflecting a post-pandemic hangover. As of Sept 25, the stock was down roughly 9% year-to-date and about 18% below its level one year prior ts2.tech. It traded near the bottom of its 52-week range ($20.92 – $30.43), weighed down by steep declines in COVID vaccine and pill sales and general pessimism on its growth prospects ts2.tech ts2.tech. In fact, Pfizer’s COVID-driven revenues
6 October 2025
 ·  ·  ·  ·  ·  ·  · 
Go toTop